Today: 13 May 2026
Medibank share price drops after results — dividend lift, premium hike and what investors watch next
19 February 2026
1 min read

Medibank share price drops after results — dividend lift, premium hike and what investors watch next

Sydney, Feb 19, 2026, 18:13 (AEDT) — After-hours

  • Medibank ended the day off 6.2% following its half-year results release.
  • The interim dividend’s up 6.4%, now at 8.3 Australian cents per share, fully franked.
  • Premiums climbed in April, putting a spotlight back on member growth and claims expenses.

Shares of Medibank Private Ltd dropped 6.2% on Thursday, closing at A$4.50. The insurer surrendered some of the previous session’s gains as investors digested its half-year results.

Medibank reported that underlying net profit after tax, which excludes investment market swings, edged down 0.3% to A$297.8 million for the six months to Dec. 31. The board, though, bumped up the interim dividend by 6.4% to 8.3 Australian cents per share, fully franked—so it comes with local tax credits. “We’ve delivered on our growth commitments,” Chief Executive David Koczkar said, highlighting stronger momentum in health insurance and the expansion of the group’s health services business.

The numbers drop just as health insurers brace for April’s price reset, after Canberra approved an average 4.41% hike in private health insurance premiums starting April 1. The government also plans to ban “product phoenixing”—a tactic where insurers shutter a product only to relaunch a near-duplicate at a steeper price. Health, Disability and Ageing

Medibank will lift its premiums by an average of 5.10% starting April 1, following the green light from the government. That’s higher than the industry average.

Medibank’s investor presentation showed group operating profit climbing 6% to A$381.7 million. Health Insurance operating profit edged up 3.5% to A$361.5 million; profits in the Medibank Health segment jumped 28.5% to A$48.3 million. Net resident policyholder numbers increased by 38,300 over the year. The company also highlighted its acquisition of Better Medical for A$163.5 million, signaling a deeper move into primary care.

Top-line gains didn’t filter through everywhere. Net investment income slid 17.1% to A$94.9 million. Medibank also pointed to A$15.0 million in one-off cybercrime expenses linked to the 2022 breach—covering security upgrades plus legal and regulatory costs.

That marked a shift from Wednesday. Back then, Australian media had reported gains for health insurers like Medibank and NIB Holdings following the premium approvals.

NIB plans to hike its health insurance premiums by an average of 5.47% starting April 1.

Medibank’s underlying net profit for the first half landed at roughly A$298 million, coming in 2% to 4% shy of forecasts, according to Citi’s Nigel Pittaway. He pointed to softer returns from the private health insurance division and rising expenses.

There’s a risk here: larger premium hikes could draw fresh attention to value for money, nudging cost-conscious customers to switch plans or exit entirely, even as hospital and medical expenses keep rising. Throw in any additional cyber charges or negative regulatory news, and that would drag on sentiment, too.

Now attention turns to broker updates and potential tweaks to FY26 forecasts before Medibank’s interim dividend dates come up. Shares go ex-dividend Feb. 26, with the payout scheduled for March 18.

Stock Market Today

  • Man Recovers $400,000 in Bitcoin After 11 Years Using Anthropic's AI
    May 13, 2026, 4:29 PM EDT. A Bitcoin holder recovered around $400,000 in BTC, locked for over a decade, with the help of Anthropic's AI chatbot Claude. The user, known as Cprkrn, had lost access after changing his wallet password while intoxicated. After years of failed attempts and trying trillions of password combinations, Claude analyzed old files from his college computer, locating an older wallet file and a mnemonic phrase that restored access to 5 BTC. At Bitcoin's current price near $79,600, his recovery underscores AI's potential in aiding crypto asset retrieval without breaking security protocols. The story serves as a reminder about the hidden value of old digital files.

Latest articles

Applied Optoelectronics Stock Surges Again as AI Data-Center Demand Outruns Supply

Applied Optoelectronics Stock Surges Again as AI Data-Center Demand Outruns Supply

13 May 2026
Applied Optoelectronics shares surged 21% Wednesday, trading at $227.05 after strong demand from AI data centers pushed first-quarter data-center revenue to $81.4 million, up from $32 million a year ago. CFO Stefan Murry said supply remains the main constraint, with demand expected to outpace output through mid-2027. AOI shipped its first volume 800G products to a hyperscale customer. The company posted a first-quarter net loss of $14.3 million.
Dow Jones Today: Why the Dow Slipped While AI Stocks Drove Wall Street Higher

Dow Jones Today: Why the Dow Slipped While AI Stocks Drove Wall Street Higher

13 May 2026
The Dow Jones Industrial Average fell 90.72 points to 49,669.84 on Wednesday, while the S&P 500 and Nasdaq rose, lifted by gains in chip and AI stocks. Producer prices jumped 1.4% in April, the largest monthly increase since March 2022. The Senate confirmed Kevin Warsh as Federal Reserve chair in a 54-45 vote. Prediction markets showed a 97% chance the Fed holds rates steady in June.
US Stocks Hit Fresh Records as Chip Rally Overpowers Hot Inflation Shock

US Stocks Hit Fresh Records as Chip Rally Overpowers Hot Inflation Shock

13 May 2026
The S&P 500 closed at 7,444.14 and the Nasdaq at 26,404.74, both record highs, while the Dow slipped 0.13% to 49,693.63. April producer prices jumped 1.4%, the largest monthly rise since March 2022, pushing back Fed rate-cut expectations. Prediction markets now see a long pause in U.S. policy easing. Tech stocks, especially AI-linked shares, led gains despite the inflation surprise.

Popular

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

13 May 2026
SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
Zip Co share price dives 34% after flat outlook jars investors; what’s next for ASX:ZIP
Previous Story

Zip Co share price dives 34% after flat outlook jars investors; what’s next for ASX:ZIP

British American Tobacco share price rises early as BAT reiterates 2026 outlook and keeps buyback running
Next Story

British American Tobacco share price rises early as BAT reiterates 2026 outlook and keeps buyback running

Go toTop